OP-1 clinical studies.
Friedlaender
G E
GE
Department of Orthopaedic Surgery, Yale University School of Medicine, New Haven, CT 06520-8071, USA.
D055396:Bone Morphogenetic Protein 2; D055419:Bone Morphogenetic Protein 7; D019485:Bone Morphogenetic Proteins / Q000627:therapeutic use*; D016025:Bone Transplantation; D054428:Chemokine CX3CL1; D020523:Chemokines, CX3C; D019743:Chemokines, CXC; D005594:Fracture Fixation, Intramedullary; D005599:Fractures, Ununited / Q000628:therapy*; D006801:Humans; D008565:Membrane Proteins; D016032:Randomized Controlled Trials as Topic; D013978:Tibial Fractures / Q000628:therapy*; D016212:Transforming Growth Factor beta
C525718:BMP2 protein, human; C525819:BMP7 protein, human; D055396:Bone Morphogenetic Protein 2; D055419:Bone Morphogenetic Protein 7; D019485:Bone Morphogenetic Proteins; C515538:CX3CL1 protein, human; D054428:Chemokine CX3CL1; D020523:Chemokines, CX3C; D019743:Chemokines, CXC; D008565:Membrane Proteins; D016212:Transforming Growth Factor beta